<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38307">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01658722</url>
  </required_header>
  <id_info>
    <org_study_id>AAB-001-ALZ-3300</org_study_id>
    <nct_id>NCT01658722</nct_id>
  </id_info>
  <brief_title>Retrieval of Patient Information After Discontinuation</brief_title>
  <acronym>RAPID</acronym>
  <official_title>A Phase 3b Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies ELN15727-301 and 302 But Did Not Enroll in Study ELN115727-351</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3b, Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in
      Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies
      ELN115727-301 and 302 but did not Enroll in Study ELN115727-351.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Dependence Scale</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Caregiver's assessment of a patient's need for assistance</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">169</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <description>Long term follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bapineuzumab</intervention_name>
    <arm_group_label>Observational</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with Alzheimer's disease who discontinued treatment in bapineuzumab Phase 3
        clinical studies (ELN115727-301/302/351) or who completed studies ELN115727-301 or 302 but
        did not enroll in study ELN115727-351
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Signed, dated, and written informed consent obtained from the subject and/or the
             subject's legally acceptable representative (LAR, if applicable) in accordance with
             local regulations.

          2. Signed, dated, and written informed consent, obtained from the subject's caregiver in
             accordance with local regulations.

          3. Subject must have participated in the Study 301, 302, or 351 and have received at
             least 1 dose of study treatment (bapineuzumab or placebo).

          4. Subject must have been off treatment for at least 12 months prior to Visit 1.

          5. Subjects must have a primary caregiver for the duration of the study.

          6. Subject's caregiver must have the ability to assess the subject and answer questions
             over the phone.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 24, 2012</lastchanged_date>
  <firstreceived_date>March 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
